Skip to main content
Figure 6 | Molecular Cancer

Figure 6

From: Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

Figure 6

Schematic diagram for finding the Wee1 gene signature available for both tumor and surrogate tissues, and its potential application to clinical research. The present study isolated a gene set that commonly showed expression changes in both TOV21G p53 positive and negative matched pair cell lines and rat skin tissues, which led to the identification of the Wee1 gene signature available as a PD biomarker for Wee1 inhibitor independent of the p53 status of the tissues analyzed. In future clinical trials, the Wee1 gene expression signature can be analyzed from both plucked hair samples and FFPE tumor samples to assess the target engagement of the Wee1 inhibitor.

Back to article page